| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza, Human | 28 | 2026 | 703 | 3.910 |
Why?
|
| Vaccination | 33 | 2026 | 1044 | 3.570 |
Why?
|
| Influenza Vaccines | 16 | 2026 | 500 | 2.850 |
Why?
|
| Rotavirus Infections | 18 | 2024 | 281 | 2.750 |
Why?
|
| Rotavirus Vaccines | 14 | 2024 | 60 | 2.720 |
Why?
|
| Gastroenteritis | 16 | 2025 | 316 | 2.590 |
Why?
|
| Hospitalization | 45 | 2026 | 1942 | 2.370 |
Why?
|
| Respiratory Tract Infections | 14 | 2025 | 293 | 2.260 |
Why?
|
| Respiratory Syncytial Virus Infections | 12 | 2026 | 385 | 1.950 |
Why?
|
| Immunization Programs | 5 | 2020 | 66 | 1.500 |
Why?
|
| Infant | 75 | 2026 | 13317 | 1.460 |
Why?
|
| Vaccines | 6 | 2023 | 384 | 1.420 |
Why?
|
| Rotavirus | 11 | 2024 | 366 | 1.280 |
Why?
|
| Immunization | 6 | 2021 | 307 | 1.240 |
Why?
|
| Health Knowledge, Attitudes, Practice | 9 | 2024 | 904 | 1.140 |
Why?
|
| Antiviral Agents | 8 | 2026 | 812 | 1.110 |
Why?
|
| Child | 72 | 2026 | 26307 | 1.080 |
Why?
|
| Child, Preschool | 60 | 2026 | 15051 | 1.070 |
Why?
|
| Hepatitis B Vaccines | 2 | 2026 | 49 | 1.060 |
Why?
|
| Mothers | 5 | 2024 | 371 | 1.020 |
Why?
|
| United States | 55 | 2026 | 11812 | 0.940 |
Why?
|
| Enterovirus Infections | 5 | 2025 | 48 | 0.910 |
Why?
|
| Respiratory Syncytial Virus, Human | 6 | 2025 | 233 | 0.890 |
Why?
|
| Autism Spectrum Disorder | 3 | 2021 | 442 | 0.880 |
Why?
|
| Texas | 17 | 2026 | 3622 | 0.870 |
Why?
|
| Hepatitis B | 1 | 2026 | 174 | 0.860 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 6 | 2025 | 188 | 0.850 |
Why?
|
| Papillomavirus Vaccines | 6 | 2021 | 111 | 0.840 |
Why?
|
| Professionalism | 1 | 2024 | 45 | 0.840 |
Why?
|
| Humans | 120 | 2026 | 131759 | 0.820 |
Why?
|
| Parents | 9 | 2024 | 1120 | 0.820 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2026 | 260 | 0.810 |
Why?
|
| Guideline Adherence | 1 | 2026 | 393 | 0.780 |
Why?
|
| Infant, Newborn | 30 | 2026 | 8594 | 0.780 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2021 | 505 | 0.760 |
Why?
|
| Adolescent | 44 | 2026 | 20987 | 0.750 |
Why?
|
| Vaccination Refusal | 2 | 2024 | 19 | 0.750 |
Why?
|
| Immunization Schedule | 6 | 2026 | 111 | 0.730 |
Why?
|
| Pediatrics | 4 | 2019 | 1232 | 0.730 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 4 | 2026 | 80 | 0.680 |
Why?
|
| Case-Control Studies | 21 | 2026 | 3451 | 0.670 |
Why?
|
| Delivery of Health Care | 2 | 2019 | 682 | 0.660 |
Why?
|
| Hospitals, Pediatric | 7 | 2024 | 793 | 0.650 |
Why?
|
| Population Surveillance | 6 | 2025 | 397 | 0.640 |
Why?
|
| Emergency Service, Hospital | 10 | 2025 | 1216 | 0.640 |
Why?
|
| Female | 69 | 2026 | 71214 | 0.640 |
Why?
|
| Reminder Systems | 3 | 2016 | 62 | 0.640 |
Why?
|
| Male | 65 | 2026 | 65274 | 0.620 |
Why?
|
| Reassortant Viruses | 3 | 2016 | 28 | 0.620 |
Why?
|
| Epidemiological Monitoring | 3 | 2018 | 69 | 0.610 |
Why?
|
| Prospective Studies | 23 | 2025 | 6507 | 0.600 |
Why?
|
| Metapneumovirus | 3 | 2025 | 53 | 0.600 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 7 | 2026 | 126 | 0.580 |
Why?
|
| Enterovirus D, Human | 3 | 2025 | 11 | 0.560 |
Why?
|
| Arbovirus Infections | 1 | 2018 | 31 | 0.550 |
Why?
|
| Fever | 3 | 2024 | 312 | 0.540 |
Why?
|
| Viruses | 3 | 2024 | 118 | 0.540 |
Why?
|
| Pregnancy Complications, Infectious | 4 | 2026 | 500 | 0.540 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2026 | 580 | 0.520 |
Why?
|
| Seasons | 9 | 2026 | 333 | 0.520 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2019 | 200 | 0.520 |
Why?
|
| Fathers | 1 | 2017 | 71 | 0.510 |
Why?
|
| Paramyxoviridae Infections | 3 | 2025 | 49 | 0.490 |
Why?
|
| Autistic Disorder | 1 | 2020 | 398 | 0.490 |
Why?
|
| Attitude to Health | 1 | 2017 | 251 | 0.470 |
Why?
|
| Acute Disease | 9 | 2025 | 1153 | 0.460 |
Why?
|
| Adenoviruses, Human | 2 | 2025 | 97 | 0.450 |
Why?
|
| Adenovirus Infections, Human | 2 | 2025 | 60 | 0.440 |
Why?
|
| Database Management Systems | 1 | 2014 | 27 | 0.440 |
Why?
|
| Papillomavirus Infections | 4 | 2020 | 389 | 0.430 |
Why?
|
| Social Media | 3 | 2021 | 119 | 0.430 |
Why?
|
| Picornaviridae Infections | 2 | 2025 | 50 | 0.430 |
Why?
|
| Caliciviridae Infections | 3 | 2025 | 289 | 0.410 |
Why?
|
| Health Education | 2 | 2013 | 229 | 0.400 |
Why?
|
| Norovirus | 3 | 2025 | 288 | 0.400 |
Why?
|
| Forecasting | 1 | 2014 | 361 | 0.390 |
Why?
|
| Enterovirus | 2 | 2024 | 52 | 0.390 |
Why?
|
| Mass Media | 1 | 2013 | 27 | 0.390 |
Why?
|
| Feces | 11 | 2025 | 725 | 0.380 |
Why?
|
| Coinfection | 4 | 2024 | 192 | 0.370 |
Why?
|
| Vaccination Coverage | 2 | 2025 | 37 | 0.370 |
Why?
|
| Genotype | 10 | 2025 | 2656 | 0.360 |
Why?
|
| Antibodies, Viral | 1 | 2018 | 1173 | 0.360 |
Why?
|
| International Classification of Diseases | 2 | 2024 | 97 | 0.350 |
Why?
|
| Child, Hospitalized | 4 | 2026 | 79 | 0.350 |
Why?
|
| Infection Control | 1 | 2013 | 163 | 0.350 |
Why?
|
| Information Systems | 2 | 2010 | 29 | 0.340 |
Why?
|
| Vaccines, Attenuated | 8 | 2022 | 174 | 0.340 |
Why?
|
| Hospital Information Systems | 1 | 2010 | 42 | 0.330 |
Why?
|
| Rhinovirus | 3 | 2025 | 65 | 0.320 |
Why?
|
| Disease Outbreaks | 3 | 2021 | 314 | 0.320 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 4052 | 0.310 |
Why?
|
| Cross-Sectional Studies | 8 | 2025 | 3836 | 0.300 |
Why?
|
| Vaccines, Synthetic | 4 | 2022 | 321 | 0.290 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 698 | 0.290 |
Why?
|
| Reimbursement Mechanisms | 1 | 2008 | 36 | 0.280 |
Why?
|
| Access to Information | 1 | 2008 | 45 | 0.280 |
Why?
|
| Pregnancy | 8 | 2026 | 7576 | 0.280 |
Why?
|
| Health Promotion | 2 | 2008 | 407 | 0.270 |
Why?
|
| Informed Consent | 1 | 2010 | 343 | 0.270 |
Why?
|
| Education, Medical, Continuing | 1 | 2008 | 134 | 0.270 |
Why?
|
| Peer Group | 1 | 2008 | 125 | 0.270 |
Why?
|
| Hospitals | 3 | 2026 | 445 | 0.270 |
Why?
|
| Insurance Coverage | 1 | 2008 | 117 | 0.270 |
Why?
|
| Communicable Disease Control | 1 | 2008 | 141 | 0.260 |
Why?
|
| Influenza B virus | 5 | 2026 | 102 | 0.260 |
Why?
|
| Pandemics | 6 | 2026 | 1165 | 0.260 |
Why?
|
| Severity of Illness Index | 5 | 2025 | 3093 | 0.240 |
Why?
|
| Adult | 11 | 2026 | 31700 | 0.240 |
Why?
|
| Cost-Benefit Analysis | 3 | 2020 | 544 | 0.240 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2026 | 59 | 0.240 |
Why?
|
| Disasters | 1 | 2007 | 102 | 0.240 |
Why?
|
| Croup | 1 | 2025 | 14 | 0.240 |
Why?
|
| Fucosyltransferases | 2 | 2015 | 25 | 0.230 |
Why?
|
| Hepatitis B virus | 1 | 2026 | 143 | 0.230 |
Why?
|
| Bronchiolitis | 1 | 2025 | 124 | 0.220 |
Why?
|
| Electronic Health Records | 2 | 2023 | 810 | 0.210 |
Why?
|
| Ambulatory Care | 2 | 2026 | 407 | 0.210 |
Why?
|
| Patient Education as Topic | 2 | 2019 | 465 | 0.210 |
Why?
|
| Drug Prescriptions | 1 | 2025 | 230 | 0.200 |
Why?
|
| Systemic Inflammatory Response Syndrome | 2 | 2023 | 209 | 0.200 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2024 | 153 | 0.200 |
Why?
|
| Connective Tissue Diseases | 1 | 2023 | 32 | 0.190 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2025 | 775 | 0.190 |
Why?
|
| Prenatal Care | 1 | 2025 | 346 | 0.190 |
Why?
|
| Pneumonia | 1 | 2025 | 344 | 0.180 |
Why?
|
| Physicians | 1 | 2008 | 634 | 0.180 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 2022 | 35 | 0.180 |
Why?
|
| Turbinates | 1 | 2021 | 13 | 0.180 |
Why?
|
| Herpesvirus 1, Cercopithecine | 1 | 2021 | 2 | 0.180 |
Why?
|
| Anti-Vaccination Movement | 1 | 2021 | 11 | 0.180 |
Why?
|
| RNA, Viral | 2 | 2021 | 512 | 0.180 |
Why?
|
| Prevalence | 4 | 2025 | 2695 | 0.180 |
Why?
|
| Young Adult | 4 | 2026 | 10099 | 0.170 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2022 | 172 | 0.170 |
Why?
|
| Family Relations | 1 | 2021 | 75 | 0.170 |
Why?
|
| Pediatricians | 1 | 2021 | 74 | 0.170 |
Why?
|
| Public Health Surveillance | 1 | 2020 | 44 | 0.170 |
Why?
|
| Dermatomyositis | 1 | 2000 | 34 | 0.170 |
Why?
|
| Cost of Illness | 4 | 2025 | 291 | 0.160 |
Why?
|
| Product Surveillance, Postmarketing | 2 | 2010 | 26 | 0.160 |
Why?
|
| Infant, Premature | 1 | 2026 | 857 | 0.160 |
Why?
|
| Muscle Weakness | 1 | 2000 | 90 | 0.160 |
Why?
|
| Mobile Health Units | 1 | 2020 | 29 | 0.160 |
Why?
|
| Semantics | 1 | 2020 | 26 | 0.160 |
Why?
|
| Communication | 2 | 2021 | 531 | 0.150 |
Why?
|
| Virus Diseases | 1 | 2022 | 285 | 0.150 |
Why?
|
| Outpatients | 1 | 2021 | 266 | 0.150 |
Why?
|
| Exanthema | 1 | 2000 | 74 | 0.150 |
Why?
|
| Family Health | 1 | 2020 | 251 | 0.150 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2020 | 123 | 0.150 |
Why?
|
| Spain | 1 | 2019 | 62 | 0.150 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2019 | 16 | 0.150 |
Why?
|
| Workflow | 1 | 2019 | 139 | 0.150 |
Why?
|
| Bacteriophages | 1 | 2020 | 100 | 0.150 |
Why?
|
| Antigens, Viral | 3 | 2024 | 395 | 0.140 |
Why?
|
| Communicable Diseases, Imported | 1 | 2018 | 6 | 0.140 |
Why?
|
| Information Dissemination | 1 | 2021 | 195 | 0.140 |
Why?
|
| Computers, Handheld | 1 | 2019 | 33 | 0.140 |
Why?
|
| Caregivers | 1 | 2024 | 585 | 0.140 |
Why?
|
| Urban Population | 2 | 2010 | 281 | 0.140 |
Why?
|
| Phylogeny | 2 | 2021 | 709 | 0.140 |
Why?
|
| Genetic Variation | 1 | 2025 | 1561 | 0.140 |
Why?
|
| Bites and Stings | 1 | 2018 | 32 | 0.140 |
Why?
|
| Chikungunya Fever | 1 | 2018 | 32 | 0.140 |
Why?
|
| Online Systems | 1 | 2017 | 17 | 0.130 |
Why?
|
| Lung Diseases | 1 | 2021 | 401 | 0.130 |
Why?
|
| Pregnancy, High-Risk | 1 | 2017 | 40 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 287 | 0.130 |
Why?
|
| Community Participation | 1 | 2017 | 43 | 0.130 |
Why?
|
| Travel | 1 | 2018 | 128 | 0.130 |
Why?
|
| Dengue | 1 | 2018 | 123 | 0.130 |
Why?
|
| Health Care Surveys | 2 | 2008 | 282 | 0.130 |
Why?
|
| Motivation | 1 | 2019 | 332 | 0.130 |
Why?
|
| West Nile Fever | 1 | 2018 | 139 | 0.120 |
Why?
|
| Poliovirus Vaccines | 1 | 2016 | 13 | 0.120 |
Why?
|
| Chickenpox Vaccine | 1 | 2016 | 14 | 0.120 |
Why?
|
| Haemophilus Vaccines | 1 | 2016 | 32 | 0.120 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2016 | 14 | 0.120 |
Why?
|
| Infectious Disease Medicine | 1 | 2016 | 13 | 0.120 |
Why?
|
| Knowledge Bases | 1 | 2016 | 40 | 0.120 |
Why?
|
| Developmental Disabilities | 1 | 2021 | 771 | 0.120 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2016 | 35 | 0.120 |
Why?
|
| Genome, Viral | 1 | 2016 | 154 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 366 | 0.120 |
Why?
|
| Computer-Assisted Instruction | 1 | 2016 | 58 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 378 | 0.110 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2016 | 140 | 0.110 |
Why?
|
| Canada | 1 | 2016 | 327 | 0.110 |
Why?
|
| Software Design | 1 | 2014 | 22 | 0.110 |
Why?
|
| Models, Organizational | 1 | 2014 | 44 | 0.110 |
Why?
|
| Statistics as Topic | 1 | 2015 | 244 | 0.110 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1406 | 0.100 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2014 | 139 | 0.100 |
Why?
|
| RNA, Messenger | 3 | 2024 | 2569 | 0.100 |
Why?
|
| Health Services Needs and Demand | 1 | 2014 | 169 | 0.100 |
Why?
|
| Interviews as Topic | 2 | 2020 | 440 | 0.100 |
Why?
|
| Logistic Models | 1 | 2017 | 1838 | 0.090 |
Why?
|
| Family Characteristics | 2 | 2025 | 98 | 0.090 |
Why?
|
| Patient Acuity | 2 | 2022 | 67 | 0.090 |
Why?
|
| Registries | 2 | 2010 | 1597 | 0.090 |
Why?
|
| Presumed Consent | 1 | 2010 | 4 | 0.080 |
Why?
|
| Hospitals, Maternity | 1 | 2010 | 8 | 0.080 |
Why?
|
| Serum | 1 | 2010 | 45 | 0.080 |
Why?
|
| Retrospective Studies | 2 | 2026 | 17662 | 0.080 |
Why?
|
| Costs and Cost Analysis | 1 | 2010 | 155 | 0.080 |
Why?
|
| Risk Factors | 4 | 2026 | 10961 | 0.080 |
Why?
|
| Age Factors | 2 | 2019 | 2872 | 0.080 |
Why?
|
| Cohort Studies | 3 | 2024 | 5122 | 0.070 |
Why?
|
| Time Factors | 3 | 2025 | 6280 | 0.070 |
Why?
|
| Urban Health Services | 1 | 2008 | 20 | 0.070 |
Why?
|
| Age Distribution | 1 | 2010 | 429 | 0.070 |
Why?
|
| Family Practice | 1 | 2008 | 88 | 0.070 |
Why?
|
| Insurance, Health | 1 | 2008 | 140 | 0.070 |
Why?
|
| Public Health Practice | 1 | 2007 | 19 | 0.070 |
Why?
|
| Louisiana | 1 | 2007 | 136 | 0.070 |
Why?
|
| Private Practice | 1 | 2007 | 22 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2015 | 3416 | 0.060 |
Why?
|
| User-Computer Interface | 2 | 2019 | 161 | 0.060 |
Why?
|
| Palivizumab | 1 | 2026 | 48 | 0.060 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2020 | 530 | 0.060 |
Why?
|
| Absenteeism | 1 | 2024 | 19 | 0.060 |
Why?
|
| Vomiting | 1 | 2025 | 105 | 0.050 |
Why?
|
| Asymptomatic Infections | 1 | 2024 | 39 | 0.050 |
Why?
|
| Health Behavior | 1 | 2007 | 390 | 0.050 |
Why?
|
| RNA, Messenger, Stored | 1 | 2023 | 6 | 0.050 |
Why?
|
| Drug Utilization | 1 | 2024 | 164 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2024 | 2146 | 0.050 |
Why?
|
| Health Personnel | 1 | 2008 | 549 | 0.050 |
Why?
|
| Diarrhea | 1 | 2025 | 311 | 0.050 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2026 | 214 | 0.050 |
Why?
|
| Hospital Costs | 1 | 2024 | 180 | 0.050 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2022 | 34 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2026 | 501 | 0.050 |
Why?
|
| Coronavirus | 1 | 2022 | 27 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 792 | 0.050 |
Why?
|
| Oseltamivir | 1 | 2021 | 19 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2022 | 124 | 0.040 |
Why?
|
| Life Support Care | 1 | 2022 | 51 | 0.040 |
Why?
|
| Immunization, Secondary | 1 | 2022 | 119 | 0.040 |
Why?
|
| Social Networking | 1 | 2020 | 16 | 0.040 |
Why?
|
| Dermatitis | 1 | 2000 | 29 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2024 | 400 | 0.040 |
Why?
|
| Length of Stay | 1 | 2026 | 1399 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2022 | 582 | 0.040 |
Why?
|
| Transients and Migrants | 1 | 2020 | 30 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 146 | 0.040 |
Why?
|
| Fatigue | 1 | 2000 | 199 | 0.040 |
Why?
|
| Public Health | 1 | 2021 | 277 | 0.040 |
Why?
|
| Oxygen | 1 | 2022 | 553 | 0.040 |
Why?
|
| Ambulatory Care Facilities | 1 | 2020 | 236 | 0.040 |
Why?
|
| Medically Uninsured | 1 | 2019 | 77 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2022 | 517 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 1236 | 0.030 |
Why?
|
| Critical Illness | 1 | 2022 | 616 | 0.030 |
Why?
|
| Machine Learning | 1 | 2021 | 375 | 0.030 |
Why?
|
| Automation | 1 | 2017 | 67 | 0.030 |
Why?
|
| Weight Loss | 1 | 2000 | 529 | 0.030 |
Why?
|
| Pediatric Obesity | 1 | 2021 | 411 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 1010 | 0.030 |
Why?
|
| Poverty | 1 | 2020 | 456 | 0.030 |
Why?
|
| Asthma | 1 | 2025 | 926 | 0.030 |
Why?
|
| Comorbidity | 1 | 2021 | 1600 | 0.030 |
Why?
|
| Consumer Health Information | 1 | 2016 | 28 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2024 | 3696 | 0.030 |
Why?
|
| Cattle | 1 | 2016 | 521 | 0.030 |
Why?
|
| Inpatients | 1 | 2019 | 544 | 0.030 |
Why?
|
| Saliva | 1 | 2015 | 137 | 0.030 |
Why?
|
| Premature Birth | 1 | 2019 | 414 | 0.030 |
Why?
|
| Algorithms | 1 | 2021 | 1685 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2021 | 12993 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2015 | 750 | 0.020 |
Why?
|
| Internet | 1 | 2016 | 423 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 5297 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2015 | 423 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 3616 | 0.020 |
Why?
|
| Obesity | 1 | 2022 | 2390 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 934 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 237 | 0.020 |
Why?
|
| Aged | 1 | 2026 | 21259 | 0.020 |
Why?
|
| Animals | 2 | 2020 | 34404 | 0.020 |
Why?
|
| Middle Aged | 1 | 2026 | 28892 | 0.010 |
Why?
|
| Teaching | 1 | 2007 | 196 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 2298 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2007 | 1457 | 0.010 |
Why?
|
| Mutation | 1 | 2015 | 6194 | 0.010 |
Why?
|